



US009408849B2

(12) **United States Patent**
Yi et al.

(10) **Patent No.:** **US 9,408,849 B2**
(45) **Date of Patent:** ***Aug. 9, 2016**

(54) **CRYSTAL ENTECAVIR, CRYSTAL ENTECAVIR FORMULATION AND METHODS FOR THE PREPARATION THEREOF**

(71) Applicant: **Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory**, Donglu, Xinchang County (CN)

(72) Inventors: **Deping Yi**, Huancheng Donglu (CN); **Zhike Tian**, Huancheng Donglu (CN); **Weidong Ye**, Huancheng Donglu (CN)

(73) Assignee: **Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory**, Huancheng Donglu (CN)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/246,029**

(22) Filed: **Apr. 4, 2014**

(65) **Prior Publication Data**

US 2014/0220120 A1 Aug. 7, 2014

Related U.S. Application Data

(63) Continuation-in-part of application No. 12/674,879, filed as application No. PCT/CN2008/001523 on Aug. 25, 2008, now abandoned, application No. 14/246,029, which is a continuation-in-part of application No. 12/527,215, filed as application No. PCT/CN2008/000249 on Jan. 31, 2008, now Pat. No. 8,937,076.

(30) **Foreign Application Priority Data**

Feb. 14, 2007 (CN) 2007 1 0004988

Aug. 23, 2007 (CN) 2007 1 0143096

(51) **Int. Cl.**

A61K 31/522 (2006.01)

A61K 9/20 (2006.01)

A61K 9/48 (2006.01)

C07D 473/18 (2006.01)

(52) **U.S. Cl.**

CPC *A61K 31/522* (2013.01); *A61K 9/2027* (2013.01); *A61K 9/2054* (2013.01); *A61K 9/4866* (2013.01); *C07D 473/18* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2007/0060599 A1* 3/2007 DiMarco C07D 473/18
514/263.37

* cited by examiner

Primary Examiner — David J Blanchard

Assistant Examiner — Daniel F Coughlin

(74) *Attorney, Agent, or Firm* — William D. Hare; McNeely Hare & War, LLP

(57) **ABSTRACT**

The present invention relates to a pharmaceutical composition for treating hepatitis B virus infection comprising crystalline entecavir as the pharmaceutically active ingredient and one or more pharmaceutically acceptable excipients. The tablet and capsule of the pharmaceutical composition have improved stability compared to that of amorphous entecavir under the conditions of light, high temperature and high humidity.

16 Claims, 2 Drawing Sheets